Evidence for decreased splanchnic glucose uptake after oral glucose administration in non-insulin-dependent diabetes mellitus
- PMID: 9410915
- PMCID: PMC508433
- DOI: 10.1172/JCI119775
Evidence for decreased splanchnic glucose uptake after oral glucose administration in non-insulin-dependent diabetes mellitus
Abstract
The role of splanchnic glucose uptake (SGU) after oral glucose administration as a potential factor contributing to postprandial hyperglycemia in non-insulin-dependent diabetes mellitus (NIDDM) has not been established conclusively. Therefore, we investigated SGU in six patients with NIDDM and six weight-matched control subjects by means of the hepatic vein catheterization (HVC) technique. In a second part, we examined the applicability of the recently developed OG-CLAMP technique in NIDDM by comparing SGU and first-pass SGU during HVC with SGU during the OG-CLAMP experiment. The OG-CLAMP method combines a euglycemic, hyperinsulinemic clamp and an oral glucose tolerance test (75 g) during steady state glucose infusion (GINF). During HVC, SGU equals the splanchnic fractional extraction times the total (oral and arterial) glucose load presented to the liver. For OG-CLAMP, SGU was calculated as first-pass SGU by subtracting the integrated decrease in GINF over 180 min from 75 g. Cumulative splanchnic glucose output after oral glucose correlated significantly between both methods and was increased significantly in NIDDM patients (73.1+/-5.1 g for HVC, 76.5+/-5.5 for OG-CLAMP) compared with nondiabetic patients (46.7+/-4.4 g for HVC, 57.5+/-1.9 for OG-CLAMP). Thus, in NIDDM patients, SGU (7.4+/-2.1 vs. 37.8+/-5.9% in nondiabetic patients, P < 0.001) and first-pass SGU (4.7+/-1.7 vs. 26.5+/-5.1% in nondiabetic patients, P < 0.01) were decreased significantly during HVC, as was SGU during OG-CLAMP (3.9+/-1.7 vs. 23.4+/-2.5% in nondiabetic patients, P < 0.0001). SGU measured during OG-CLAMP correlated significantly with SGU (r = 0.87, P < 0.05 for NIDDM patients; r = 0.94, P < 0.01 for nondiabetic patients) and first-pass SGU (r = 0.87, P < 0.05 for NIDDM patients; r = 0.84, P < 0.05 for nondiabetic patients) during HVC. In conclusion, (a) SGU after oral glucose administration is decreased in NIDDM as measured by both methods, and (b) SGU during the OG-CLAMP is well-correlated to SGU and first-pass SGU during HVC in NIDDM. The decrease in SGU in NIDDM might contribute to postprandial hyperglycemia in diabetic subjects.
Similar articles
-
A noninvasive method to measure splanchnic glucose uptake after oral glucose administration.J Clin Invest. 1995 May;95(5):2232-8. doi: 10.1172/JCI117913. J Clin Invest. 1995. PMID: 7738188 Free PMC article.
-
Free fatty acids reduce splanchnic and peripheral glucose uptake in patients with type 2 diabetes.Diabetes. 2002 Oct;51(10):3043-8. doi: 10.2337/diabetes.51.10.3043. Diabetes. 2002. PMID: 12351445 Clinical Trial.
-
Insulin dose-response curves for stimulation of splanchnic glucose uptake and suppression of endogenous glucose production differ in nondiabetic humans and are abnormal in people with type 2 diabetes.Diabetes. 2004 Aug;53(8):2042-50. doi: 10.2337/diabetes.53.8.2042. Diabetes. 2004. PMID: 15277384
-
Role of liver in pathophysiology of NIDDM.Diabetes Care. 1992 Mar;15(3):430-41. doi: 10.2337/diacare.15.3.430. Diabetes Care. 1992. PMID: 1559410 Review.
-
Insulin resistance seen in non-insulin dependent diabetes mellitus and hypertension.Hypertens Res. 1996 Jun;19 Suppl 1:S61-4. doi: 10.1291/hypres.19.supplementi_s61. Hypertens Res. 1996. PMID: 9240767 Review.
Cited by
-
Portal glucose infusion-glucose clamp measures hepatic influence on postprandial systemic glucose appearance as well as whole body glucose disposal.Am J Physiol Endocrinol Metab. 2010 Feb;298(2):E346-53. doi: 10.1152/ajpendo.00280.2009. Epub 2009 Nov 24. Am J Physiol Endocrinol Metab. 2010. PMID: 19934401 Free PMC article.
-
A physiological increase in the hepatic glycogen level does not affect the response of net hepatic glucose uptake to insulin.Am J Physiol Endocrinol Metab. 2009 Aug;297(2):E358-66. doi: 10.1152/ajpendo.00043.2009. Epub 2009 May 26. Am J Physiol Endocrinol Metab. 2009. PMID: 19470836 Free PMC article.
-
Hepatic glycogen supercompensation activates AMP-activated protein kinase, impairs insulin signaling, and reduces glycogen deposition in the liver.Diabetes. 2011 Feb;60(2):398-407. doi: 10.2337/db10-0592. Diabetes. 2011. PMID: 21270252 Free PMC article.
-
Correcting Postprandial Hyperglycemia in Zucker Diabetic Fatty Rats With an SGLT2 Inhibitor Restores Glucose Effectiveness in the Liver and Reduces Insulin Resistance in Skeletal Muscle.Diabetes. 2017 May;66(5):1172-1184. doi: 10.2337/db16-1410. Epub 2017 Feb 28. Diabetes. 2017. PMID: 28246292 Free PMC article.
-
The Importance of the Mechanisms by Which Insulin Regulates Meal-Associated Liver Glucose Uptake in the Dog.Diabetes. 2021 Jun;70(6):1292-1302. doi: 10.2337/db20-1271. Epub 2021 Mar 23. Diabetes. 2021. PMID: 33757993 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous